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Abstract
It is now well-established that the macrophage and microglial response to CNS demyelination
influences remyelination by removing myelin debris and secreting a variety of signaling mole-
cules that influence the behaviour of oligodendrocyte progenitor cells (OPCs). Previous studies
have shown that changes in microglia contribute to the age-related decline in the efficiency of
remyelination. In this study, we show that microglia increase their expression of the proteogly-
can NG2 with age, and that this is associated with an altered micro-niche generated by aged,
but not young, microglia that can divert the differentiation OPCs from oligodendrocytes into
astrocytes in vitro. We further show that these changes in ageing microglia are generated by
exposure to high levels of TGFβ. Thus, our findings suggest that the rising levels of circulating
TGFβ known to occur with ageing contribute to the age-related decline in remyelination by
impairing the ability of microglia to promote oligodendrocyte differentiation from OPCs, and
therefore could be a potential therapeutic target to promote remyelination.
KEYWORDS
ageing, extracellular matrix, microglia, oligodendrocyte, progenitor cells
1 | INTRODUCTION
Remyelination is an important regenerative process in the CNS in which
new myelin sheaths are restored to demyelinated axons by oligodendro-
cytes which are newly generated by adult oligodendrocyte progenitor
cells (OPCs) (Franklin and ffrench-Constant, 2017). This results in the
restoration of saltatory conduction, which is lost during demyelination,
and protection from irreversible axonal atrophy (Irvine & Blakemore,
2008; Smith, Blakemore, & Mcdonald, 1979). Remyelination is con-
trolled by a complex interplay of multiple molecules and pathways that
have either facilitatory or inhibitory effects on the proliferation, migra-
tion and differentiation of adult OPCs (Franklin and ffrench-Constant,
2017). One of the main rate limiting steps in remyelination is the effi-
ciency of OPC differentiation. This is especially evident in multiple
sclerosis (MS), a chronic demyelinating disease often of several decades'
duration: chronic demyelinated lesions frequently contain oligodendro-
cyte lineage cells that have failed to undergo full differentiation into
myelin sheath-forming cells (Chang, Tourtellotte, Rudick, & Trapp,
2002; Kuhlmann et al., 2008; Wolswijk, 1998).
The molecular mediators of remyelination are produced by a vari-
ety of cell types present within demyelinating lesions. These include
microglia, the resident immune cells of the CNS, which are now recog-
nized to play a major role in CNS remyelination (Lloyd & Miron, 2016;
Rawji, Mishra, & Yong, 2016). Microglia affect OPC differentiation rate
through the clearance of myelin debris (which is inhibitory to OPC dif-
ferentiation) (Kotter, Li, Zhao, & Franklin, 2006; Natrajan et al., 2015)
and by secreting pro-regenerative factors (Miron & Franklin, 2014;
Miron et al., 2013).
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Previous studies have identified the extracellular matrix (ECM) as
a critical factor regulating OPC differentiation during remyelination
(Lau et al., 2012). For example, chondroitin sulfate proteoglycans
(CSPGs), which are deposited by different cell types in demyelination
lesions, are inhibitory to OPC differentiation and remyelination
(Keough et al., 2016). Since microglia cells compose a large compo-
nent of the cells present within demyelinating lesions, it is conceivable
that they too contribute to the ECM composition of a lesion. To test
this, we have developed a protocol for capturing the ECM environ-
ment associated with microglia (the micro-niche). Moreover, since
TGFβ levels increase with ageing and have been shown to negatively
affect hippocampal neurogenesis in the CNS (Buckwalter et al., 2006;
Carlson et al., 2009; Doyle, Cekanaviciute, Mamer, & Buckwalter,
2010), we hypothesized that TGFβ-mediated effects on the microglial
micro-niche might contribute to the age-related decline in the effi-
ciency of remyelination (Cantuti-Castelvetri et al., 2018; Miron et al.,
2013; Ruckh et al., 2012; Shields, Gilson, Blakemore, & Franklin,
1999; Sim, Zhao, Penderis, & Franklin, 2002).
2 | MATERIALS AND METHODS
2.1 | Animal husbandry
Only Sprague Dawley rats were used for this study. Rats were bred and
raised at the Animal Facility at the University of Cambridge. All animals
were fed standard diet and were kept under 12 hr cycles of light and
darkness. All animals used for experiments were sacrificed by schedule
1 approved methods, according to the requirements and regulations set
by the United Kingdom Home Office.
2.2 | Induction of white matter demyelination
In order to induce demyelination, female Sprague–Dawley rats (Harlan
Laboratories) of 18 months of age were used. The rats were anesthe-
tized with buprenorphine (0.03 mg/kg, s.c.) and 2.5% isoflurane. Demy-
elination was induced by stereotaxic injection of 4 μL of 0.01%
ethidium bromide (EB) into the caudal cerebellar peduncles (CCPs), as
previously described (Woodruff & Franklin, 1999). EB was delivered at
a rate of 1 μL/min. After EB delivery the injection needle remained in
position for additional 4 min.
2.3 | Isolation and culture of aged and young
microglia
Neonatal (P0-P20), young adult (P30-P90), and aged (18–24 months)
rats were decapitated after lethal injection of phenobarbital. Brains
were removed shortly after death (including cerebrum and cerebellum)
and placed into ice cold HALF isolation medium (Hibernate A Low
Fluorescence), supplemented with 2% of B27. Meninges, olfactory
bulbs and remains of spinal cord (if present) were removed and brain
tissue was chopped mechanically into 1 mm pieces using sterile scalps.
The minced tissue was spun down in 100 g for 2 min in RT. Brain tis-
sue was then suspended in dissociation solution (34 U/mL papain
[Worthington], 20 μg/mL DNAse Type IV [Gibco] in HALF) for
30 (neonatal) to 40 (adult) min in 37C, on a shaker set to 55 RPM.
Digestion was stopped by adding cold HBSS (Hank's Balanced Salt
Solution, no magnesium/calcium; Gibco). The tissue was centrifuged
for 5 min, in 250 g. Supernatant was completely aspirated and tissue
was re-suspended in neutralizing solution (HALF+ 2% B27+ 2 mM
sodium-pyruvate) for 5 min in RT. In order to create a single cell sus-
pension, cells were first titurated using a 5 mL serological pipette and
subsequently three fire polished glass pipettes in decreasing opening
sizes. After each trituration step the tissue suspension was allowed
to sediment and the supernatant, containing the cells, was trans-
ferred into a fresh tube, while being passed through a 70 μm cell
strainers to ensure single cell suspension. After removing the
supernatant each time, 2 mL of fresh neutralizing solution were
added to the remaining tissue. After the whole tissue was passed
though the cell strainer, a 90% pre-filtered (20 μn filters) isotonic
Percoll solution (GE Healthcare, diluted in 10× PBS pH 7.2 [Gibco])
was added. Final Percoll concentration of 22.5% was achieved by
adding phenol-red free DMEM/F12 (Dulbecco's Modified Eagle
Medium/Nutrient Mixture F-12; Gibco). The single cell suspension
was then centrifuged for 20 min in 800 g. This resulted in separa-
tion of debris and cells. Myelin debris was removed and the cells
were washed using HBSS. Cells were then incubated for 1 min in
Red Blood Cell lysis buffer (RBC lysis buffer; R7757; Sigma-Aldrich)
in order to remove contaminating red blood cells. Solution was then
topped up by HBSS and centrifuged again. A2B5+ cells were
removed using MACS. Following OPC (aged or young) MACS isola-
tion, A2B5 negative cells were centrifuged (300 g, 5 min) and cell
pellet was re-suspended in DMEM-F12 supplemented with 10%
FBS (Fetal Bovine Serum) for ghost experiments, or OPC modified
media for conditioned media experiments. Cells were plated
densely in untreated suspension plates for overnight recovery.
Next day, cells were detached from the suspension plates using ice
cold HBSS supplemented with 5 mM EDTA. Cells were incubated in
detachment solution in 4C for 15–20 min and then removed using
a pipette. The cell suspension was then centrifuged (300 g, 5 min)
and re-suspended in 90 μL MWB with 10 μL anti-Rat-CD11b mag-
netic micro beads (Miltenyi; cat#130-105-634) for every 10 million
cells for 15 min in 4C. Cells were washed using cold 8 mL MWB
and then pelleted again (300 g, 5 min). Cells were then loaded to a
MS column according to company instructions (Myltenyi).
Cells intended for ghost preparations were plated densely in
48 well plates, 40 K cells per well in OPCM (see table below) or
DMEM-F12 supplemented with 10% FBS. If serum based media
was used, all comparisons were made to cells cultured in serum
media as well. Cells were let to recover for 48 hr with/without TGFβ
(Peprotech) and TGFβ inhibitor (SB431542, Tocris Bioscience)/BMP
inhibitor (LDN-193189, CELL guidance systems) before media was
completely removed and ddH2O was added. Plate was immediately
placed in dry ice for instant freeze. Plates were later kept for short term
in −20C, or long term in −80C. Before use, plates were defrosted and
the water was removed completely before new cells were plated on
top of the ghosts.
For conditioned media experiments, cells were plated in density of
40,000 cells per well onto 24 well plates using OPC media (OPCM).
After overnight recovery, media was completely removed and replaced
with fresh OPCM supplemented with either TGFβ (Peprotech) or TGFβ
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inhibitor (SB-431542, Tocris). Cells were cultured for 48 hr, afterwards
media was removed, filtered using 22 μm filters to remove any cell
debris and was frozen immediately using dry ice. Conditioned media
was stored in −80C until use.
2.4 | Cells immunohistochemistry
At the end of each in vitro experiment, cells were fixed by adding 4%
PFA to each well and incubating in RT for 10 min. Cells were then
washed twice using PBS (5 min each wash, RT, shaking). Cell nuclei
were labeled with 2 μg/mL Hoechst 33342 (Sigma). Before applying
primary antibodies, cells were blocked using 5% normal donkey serum
(NDS) for 20 min, RT. For intracellular staining, 0.1% Triton was added
to the blocking solution. Primary antibodies (see Table 1) were diluted
in PBS+ 5% NDS and samples were incubated overnight in 4C. Fol-
lowing incubation, samples were washed twice with PBS (10 min, RT,
shaking) and secondary antibodies were added. Secondary antibodies
were diluted in PBS+ 5% PBS, and samples were incubated in RT for
2 hr. Following incubation, samples were washed 3 times with PBS,
10 min each time. Second wash included Hoechst 33342 for nuclear
staining (2 ng/mL). Image acquisition was performed using a Leica-SP5
microscope (Leica) and LAS software (Leica) or a Zeiss Observer A1
inverted microscope (Zeiss) and Zeiss Axiovision software. For each
well (in 48 well plate) 3–4 images were taken in randomly selected
areas. Further image processing and analysis was performed using the
ImageJ software package. Images quantification was done using Cell-
Profiler software (Broad Institute, Harvard University). In total, for each
condition, a minimum of 100 cells were counted.
2.5 | qRT-PCR
RNA was isolated from acutely purified OPCs and microglia or from cul-
tured OPCs and microglia using Qiagen RNeasy Micro Kit, or Directzol
RNA MicroPrep Kit (Zymo Research; cat#R2061). Isolated RNA was
immediately frozen using dry ice and was further stored in −80C. RNA
quantities were measured using Nanodrop 2000 (Thermo Scientific).
cDNA was generated using Qiagen QuantiTect Reverse Transcription Kit
according to the instructions of the manufacturer (Qiagen; 205310). For
RT-qPCR, primers were acquired from KiCqStart SYBR Primers (SIGMA-
ALDRICH) and used at a concentration of 300 μM (see Table 2). Primer
efficiency was validated for all primers (90%–110%). cDNA, primers, and
the Syber Green Master Mix (Qiagen; 204,141) were mixed as instructed
by the manufacturer, and RT-qPCR and melting curve analysis were
performed on Life Technologies Quantstudio 6 Flex Real-Time PCR Sys-
tem. Fold changes in gene expression were calculated using the delta
delta Ct method in Microsoft Excel using TATA box binding protein (Tbp)
as a control gene. Statistical significance was determined using two-tailed
unpaired t tests assuming equal variances.
2.6 | Statistics
Statistical analysis was performed on GraphPad Prism 7 (GraphPad
Software, Inc.). Immunohistochemical staining was identified using
CellProfiler and CellProfiller Analyst (Carpenter et al., 2006) was used
for machine learning cell identification and results were compared
using suitable statistical tests. If >2 groups were present, a one-way
analysis of variance (ANOVA) test was performed, followed by appro-
priate post test in order to compare individual groups (Dunnett). For
all statistical analysis, differences between groups were considered
significant at p value < .05. Graphs were produced using GraphPad
Prism or RStudio.
3 | RESULTS
3.1 | Effects of microglial ECM on OPCs
To investigate the potential effect of microglia ECM molecules on OPC
differentiation in isolation of possible effects mediated by secreted
factors, we developed a protocol that yielded preparations of microglia
membrane molecules and ECM depositions on which OPCs could be cul-
tured. We termed these preparations microglial “ghosts” (Figure 1a). In
brief, whole brains of young adult and aged rats were lysed and single cell
suspensions generated. First, MACS (Magnetic Activated Cell Sorting) for
A2B5+ cells was used to remove OPCs. Microglia were then isolated
using MACS for cells expressing the microglial marker CD11B+. We
established primary microglia cultures (>80% CD11B+ or IBA1+ cells)
from both neonatal/young rats, as well as aged rats (Figure 1b,f). For
ghost preparations, microglia were cultured in PDL coated plates for
48 hr before being lysed by ddH2O (see Figure 1a for schematic descrip-
tion). This yielded substrates comprising microglia membrane bound mol-
ecules and microglia-associated ECM, but lacking active microglia (the
method is similar to that used for astrocytes by Keough et al., [2016]).
Neonatal OPCs were then plated on the microglial “ghosts” generated
from microglia. When OPCs were plated on ghosts from naïve young
microglia there was no significant change in OL or astrocyte generation
as shown by CNP (Figure 1c) and GFAP (Figure 1d) staining when com-
pared with PDL control wells. We next asked whether ghosts generated
TABLE 1 Primary antibodies
Antibody Dilution Vendor Catalog#
Mouse anti-A2B5 (IgM) 1:300 Milipore MAB312
Mouse anti-CD11B 1:300 Serotec MCA275R
Mouse anti-CNPase 1:300 Abcam ab6319
Mouse anti-O4 (IgM) 1:1000 R&D systems MAB1326
Rabbit anti-NG2 1:300 Milipore MAB5320
Goat anti-IBA1 1:500 Abcam ab5076
Goat anti-OLIG2 1:500 R&D systems AF2418
Chicken anti-GFAP 1:1000 Abcam ab4674
TABLE 2 RT-qPCR primers
Gene name Sequence
Cd44 50—AAGATTTTATCTCCAGCACC—30
50—CTGTCTATATCAGTCATCCTGG—30
Cspg4 50—ACAAGCTCAAGAATTTCCAC—30
50—TGAAGTTCCCTGTAGTGTAAG—30
Fn1 50—AAGCCAATAGCTGAGAAATG—30
50—AAGTACAGTCCACCATCATC—30
Tbp 50—CATCATGAGAATAAGAGAGCC—30
50—GGATTGTTCTTCACTTTGG—30
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from activated microglia would affect OPCs properties. We treated
microglia with TGFβ since (a) it is known to alter ECM production in other
cell types (Ignotz & Massagué, 1986; Laping et al., 2002), (b) microglia
express high levels of TGFβ receptors (Lavin et al., 2014), and (c) it is
present in MS lesions (De Groot, Montagne, Barten, Sminia, & Van Der
Valk, 1999). We treated microglia with increasing concentrations of TGFβ
(0–20 ng/mL) for 48 hr prior to generating ghosts. OPCs plated on
ghosts derived from microglia treated with 10–20 ng/mL of TGFβ
showed significantly increased expression of GFAP and astrocyte forma-
tion when compared with PDL coated control wells (p value < .05, n = 5)
(Figure 1e,g). Although the origin of the astrocytes in the culture cannot
be unequivocally stated to arise from OPCs and not from a minority of
contaminating astrocytes, it is likely to be the former since (a) isolation of
OPCs using A2B5 antibodies does not result in significant astrocyte con-
tamination and (b) all of the astrocytes had a morphology (long separated
processes) typical of astrocytes generated by OPCs (Raff, Miller, & Noble,
1983; Tanner, Cherry, & Mayer-Proschel, 2011).
3.2 | TGFβ alters neonatal microglial-
associated ECM
We next asked if we could identify the changes elicited in microglia
by exposure to TGFβ. The effect of TGFβ was tested on young
microglia in vitro by measuring mRNA levels of Cspg4, Fn1, and Cd44
(genes coding for the ECM molecules, NG2, Fibronectin, and CD44,
respectively). qRT-PCR revealed that 48 hr treatment with 10–20 ng/mL
FIGURE 1 TGF β activated microglia surface molecules alter OPC differentiation in vitro. (a) A schematic description of the protocol used for generating
microglia ghosts. A2B5 MACS was used to remove OPCs from cell suspension. After overnight recovery, microglia were isolated using CD11B labeled
magnetic microbeads. Cells were plated, and lysed using ddH2O after 48 hr in culture. (b) 80% of the cells cultured from both young and aged adults
following CD11B microbeads isolation were either CD11B+ or IBA1+ microglia. (c) Neonatal OPCs (isolated using A2B5 MACS) cultured on young
microglia ghosts do not show any change in differentiation capacity (n = 3, p value > .05). (d) Neonatal OPCs cultured on top of neonatal microglia
ghosts, show a not significant change in GFAP expression (ratio paired t test, n = 5, p value > .05), with specific culture presenting high percentages of
astrocyte formation. (e) Neonatal OPCs cultured on top of TGFβ1 treated young microglia ghosts show significant increased expression of GFAP (one
way ANPVA, n = 4, p value < .05) in a dose dependent manner. (f) Representative images of cultured microglia (young and aged). (g) Representative
images of OPCs cultured on top of control PDL or aged microglia ghosts. OPCs were cultured for 4–5 days in serum free medium, and were stained for
GFAP (red) to identify astrocytes formation and NG2 (white) and O4 (green) to identify OL lineage cells (scale bar represents 100 μm)
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TGFβ1 induced an increase in the expression of these three genes
(Figure 2a), an effect that was eliminated by the presence of TGFβ inhibi-
tor SB-431542 (5 μM) (Inman et al., 2002) (Figure 2a). We did not
observe changes in cell viability when adding TGFβ inhibitor SB-431542
(data not shown). These results are consistent with a previous study
(Sugimoto et al., 2014), which showed that following stroke, rat microglia
express NG2 on exposure to TGFβ.
We further verified this effect by immunostaining TGFβ1-treated
young microglia for NG2 (Figure 2b). As predicted, young microglia
treated with TGFβ1 (20 ng/mL) for 48 hr in vitro showed a significant
increase in the percentage of NG2+ cells (Figure 2b,c). The addition of
TGFβ inhibitor SB-431542 to culture did not reduce the number of
NG2+ cells, in contrast to the reduction in mRNA levels (possibly due
to longer half life of the protein versus the mRNA). We therefore con-
cluded that TGFβ induced changes in the microglia-generated ECM in
a way which promoted astrocyte formation by OPCs.
3.3 | Aged microglia show ECM signature similar to
TGFβ treated microglia
Since circulating TGFβ levels increase with ageing (Buckwalter et al.,
2006; Carlson et al., 2009), we next tested whether aged microglia
present similar ECM composition to TGFβ treated young microglia
due to their long exposure to TGFβ throughout adult life. When
exploring published RNA sequencing databases (Hickman et al., 2013),
we identified multiple membrane associated molecules that show
increased levels of expression in aged microglia (Figure 3a). Further
analysis using Fluorescence Activated Flow Cytometer (FACS)
revealed that aged rats have significantly higher numbers of microglia
(labeled by CD11B) (Figure 3b), and a significantly higher percentage
of NG2 positive labeled microglia (%CD11B+NG2+/CD11B+)
(Figure 3c,d). We further verified this by culturing young and aged
microglia following CD11B+ MACS sorting and confirmed that a sig-
nificantly higher proportion of NG2+CD11B+ cells when compared
with young microglia (Figure 3g). Even though NG2 is usually used for
identifying OPCs in the CNS, our cells were not positive for OLIG2, a
marker of oligodendrocyte lineage cells, nor did they show the mor-
phology of oligodendrocyte lineage cells. In contrast, many of the
NG2+ cells had microglial morphology, although some did not show
high expression of CD11B (Figure 3e,f). Although there was no signifi-
cant difference in the percentages of NG2+/CD11B− cells between
cultures (Figure 3h), we cannot rule out the possibility of infiltration of
other cell types, such as pericytes, which can express also NG2 (Özen
et al., 2014).
FIGURE 2 TGFβ alters the expression of surface molecules in young microglia. (a) Young microglia treated in vitro (48 hr) with TGFβ1 exhibit
increase in mRNA expression of multiple surface antigens, such as Fn1, Cspg4, and Cd44, quantified by qRT-PCR (n = 3). The increase in mRNA
expression is eliminated in the presence of the TGFβ small molecule inhibitor (SB-432541, 5 μM). (b) in vitro quantification of young microglia
cultured in the presence of TGFβ1 (20 ng/mL) with or without TGFβ inhibitor (SB-432541, 5 μM) (n = 4, p value < .01). (c) IHC of microglia
treated with TGFβ co-expressing NG2 (green) and microglia marker IBA1 (red)
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3.4 | Aged microglial ghosts recapitulate TGFβ
treated microglia effects
Having found increased expression of NG2 and other ECM molecules
in aged microglia (Figure 3), we asked whether this was enough to
elicit changes in OPC differentiation in a similar fashion to the effect
we observed when using TGFβ treated young microglia. Similar to the
previous experiment, we cultured aged microglia for 48 hr prior to
microglial ghost generation. OPCs were then plated on top of these
ghosts and the extent of astrocyte formation was assessed by staining
for GFAP. OPCs plated on top of aged microglia ghosts had signifi-
cantly increased generation of astrocytes when compared with PDL
FIGURE 3 Changes in aged microglia surface molecules. (a) Published RNA-seq data show increases in expression of multiple proteoglycan genes in
aged microglia when compared with young microglia cells (Hickman et al., 2013). (b) FACS isolation of young (2–4 months old) and aged
(18–22 months old) microglia using CD11B antibodies reveals a significant increase in microglia proportions in aged rats (paired t test, p value < .05,
n = 3). (c) FACS analysis of the proportion of NG2+ cells out of total CD11B+ cells show a significant increase in aged rats (paired t test, p value <0.005,
n = 3). (d) Example of FACS scatterplot of aged microglia. (e) Representative images of young and aged microglia cultured in vitro and stained for IBA1,
CD11B (microglia markers), and NG2. (f) Small numbers of NG2+/CD11B− cells with a flat morphology were also detected. (g) Proportions of NG2+
are higher in aged microglia acutely isolated using CD11B MACS and cultured 24–48 hr in vitro (paired t test, p value < .05, n = 3). (h) There was no
significant difference in the percentage of these cells between aged and young microglia preparations (scale bar represents 100 μm)
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control wells (Figure 4a,d,e). We then asked whether this effect could
be recapitulated using aged microglia conditioned media. For this,
microglia were cultured for 48 hr before retrieving the conditioned
media. This conditioned media was mixed in a 1:1 ratio with fresh
media. OPCs that were grown in medium conditioned by aged microglia
did not show an increase in astrocyte formation (Figure 4c), supporting
the inference that ECM components produced by microglia were
responsible for the differentiation effects described rather than
secreted factors. The lack of effect using conditioned media could also
be due to technical reasons such as shorter conditioning time leading to
lower concentrations of secreted molecules in the conditioned media.
As BMP signaling has previously been shown to promote the gen-
eration of astrocytes by OPCs (Mabie et al., 1997), we tested whether
this might be the mechanism underlying the astrocyte formation by
ghosts derived from aged microglia. OPCs cultured on aged ghosts in
the presence of LDN-193189, a small molecule BMP inhibitor, did not
show increased astrocyte formation (Figure 4b), suggesting that the
effect exerted by the microglia ghosts was via the activation of BMP
signaling in OPCs.
3.5 | Aged microglia express NG2 following
demyelination
We next tested the expression of NG2 by aged microglia in vivo. Focal
areas of spinal cord white matter demyelination was induced in aged rats
(>18 months) by the injection of ethidium bromide (EB). At 5 days post
lesion-induction many cells were positive for both CD11B and NG2 within
the lesion area (Figure 5b). There were also a small number of double posi-
tive cells in normal appearing white matter of aged rats (Figure 5a).
3.6 | TGFβ directly inhibits OPC differentiation
The effects of TGFβ on microglia surface antigens prompted us to test
the direct effects of TGFβ on OPC differentiation. Previous studies
have identified TGFβ as a promoter of OPC differentiation (McKinnon,
Piras, Ida, & Dubois-Dalcq, 1993; Palazuelos, Klingener, & Aguirre,
2014). To test this, neonatal OPCs (isolated using A2B5 MACS) were
cultured in serum free media, which was supplemented by TGFβ1
(5–20 ng/mL), with or without the TGFβ inhibitor SB-431542 (5 μM)
(Figure 6). Cells were cultured for 6 days in vitro before differentiation
was assessed by immunostaining with the oligodendrocyte differentia-
tion marker CNPase. In the presence of 20 ng/mL TGFβ1, there was a
significant reduction in OPC differentiation compared with controls
(Figure 6a), an effect that was eliminated by the TGFβ inhibitor (SB-
431542) (Figure 6b). We further tested the specificity of TGFβ1 effects
on OPCs, by adding the BMP inhibitor LDN-193189 to cultures treated
with TGFβ1 (Figure 6c). LDN-193189 did not ameliorate the effects of
TGFβ. Since the two inhibitors act through different receptors, this
enabled us to identify the pathway by which TGFβ1 affected OPCs
(Figure 6d).
4 | DISCUSSION
OPCs can differentiate into oligodendrocytes, Schwann cells, and,
albeit infrequently, into astrocytes (Assinck et al., 2017; Zawadzka
et al., 2010). Here, we show that ECM deposited by TGFβ treated and
aged microglia can directly alter the fate choice of OPCs, directing
FIGURE 4 Aged microglia surface molecules alter OPC differentiation in vitro. (a) Neonatal OPCs cultured on top of aged microglia ghosts show
significant increased expression of GFAP (ratio paired t test, n = 5, p value < .05). (b) Culturing neonatal OPCs on young or aged microglia ghosts
in the presence of BMP inhibitor (LDN-193189) blocks the differentiation into astrocytes and GFAP expression (ratio paired t test, n = 3, p value
< .05). (c) OPCs cultured with aged microglia conditioned media (CM) do not show upregulation in astrocyte formation (p value > .05, n = 3). (d,e)
Representative images of OPCs cultured on top of control PDL or aged microglia ghosts. OPCs were cultured for 4–5 days in serum free medium,
and were stained for GFAP (green) to identify astrocytes formation (scale bar represents 100 μm)
BAROR ET AL. 7
them toward an astrocytic fate. The effect of ECM and cell to cell con-
tact on OPCs has been shown in relation to other cell types. For
example, neurons can control their own myelination, both by secreting
neurotransmitters (Gautier et al., 2015), but also by expressing specific
surface molecules that inhibit OLs from wrapping them with myelin
(Redmond et al., 2016). Similarly, experiments with astrocytes show
that they generate ECM that prevents OPC differentiation in vitro
molecules (Keough et al., 2016). Here, we show that microglial ECM
can influence cell fate decisions by OPCs, and that this, in part,
depends on BMP signaling. BMP signaling relies on the phosphoryla-
tion of SMAD1/5/8 by ALK2/3 (Figure 5d). Using small molecule
inhibitor (LDN-193189) which specifically targets ALK2/3, we were
able to block the induction of GFAP in OPCs cultured on microglia
ghosts. These results are consistent with previous studies which have
shown that BMP signaling induces astrocytic fate in OPCs and other
CNS progenitor cells (Gross et al., 1996; Mabie et al., 1997; Petersen
et al., 2017).
Using microglia ghost preparations, we have ruled out the possi-
ble effects of microglia secreted factors, as there are no viable cells
and secreted factors are removed by aspirating the cell media and
replacing it with ddH2O. The use of conditioned media from aged
microglia did not affect the behavior of the OPCs, in contrast to previ-
ous reports using conditioned media from activated microglia (Miron
et al., 2013; Yuen et al., 2013). This could be due to limited time the
microglia were cultured before media was taken, as it is possible that
this was not enough time for substantial concentration of factors to be
released into the media in sufficient concentrations. Moreover, in previ-
ous reports the microglia were activated by potent agents (e.g., LPS)
which are likely to cause significantly higher expression of secreted fac-
tors. In contrast, treatment with TGFβ, an anti-inflammatory cytokine,
that we have used in this study promotes production of ECM and mem-
brane bound molecules (Laping et al., 2002).
4.1 | TGFβ changes the microglial micro-niche
Since naïve young microglia ghosts did not significantly affect OPC
differentiation (Figure 1b,c), unlike the effects shown previously by
naïve astrocytes (Keough et al., 2016), we considered whether acti-
vated microglia more similar to a state likely to be present in demyeli-
nated lesions would have a different effect. We used TGFβ to activate
the microglia since it has been shown previously to be present in ele-
vated levels in MS lesions (De Groot et al., 1999) and circulating blood
of MS patients (Nicoletti et al., 1998). Moreover, TGFβ is known to
play a pivotal role in microglia development, and microglia express
higher levels of the TGFβ receptors than other tissue resident macro-
phages (Butovsky et al., 2014; Hickman et al., 2013; Lavin et al.,
2014). TGFβ has been shown to promote the expression of fibronec-
tin, which inhibits remyelination (Stoffels et al., 2013) and other ECM
FIGURE 5 NG2 positive microglia present in NAWM and demyelinating lesions in aged rats. (a) NAWM (normal appearing white matter) in aged
rats was imaged for CD11B (identification of microglia) and NG2. Several microglia were double labeled. (b) 5 days after the induction of
demyelinating lesion, multiple microglia cells expressed high reactivity to NG2 staining. Green arrows represent CD11B + NG2− cells, red arrows
point out CD11B − NG2+ cells and yellow arrows point to CD11B + NG2+ cells
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molecules in different cell types (Ignotz & Massagué, 1986; Laping
et al., 2002; Roberts et al., 1988). Following stroke, TGFβ is linked to
upregulated NG2 expression in microglia (Sugimoto et al., 2014).
Expression of NG2 in microglia has been associated previously with
lower phagocytic capacities (Zhu et al., 2012). Moreover, microglia in
NG2 knockout mice show increased expression of neurotrophic fac-
tors and decreased expression of pro-inflammatory markers following
facial nerve axotomy (Zhu et al., 2016).
These findings, in combination with rising levels of TGFβ with ageing
(Carlson et al., 2009), position TGFβ as a leading candidate for explaining
the underlying mechanisms that alter microglia membrane bound pro-
teins. Consistent with these studies, we also show that TGFβ can induce
the expression of NG2 in microglia in vitro, and furthermore can induce
an “aged like” membrane bound proteins signature. TGFβ exerts its
effects in cells through phosphorylation of SMAD2/3 by ALK4/5/7.
Using ALK4/5/7 specific small molecule inhibitor (SB-431542) (Inman
et al., 2002; Laping et al., 2002), we show that these effects are abol-
ished and thus the increased expression of NG2 by microglia is pre-
vented. We therefore conclude that TGFβ alters microglia in such a way
that it activates BMP signaling in OPCs, driving them toward astrocyte
generation. Although our primary focus has been on NG2 expression, we
do not exclude the involvement of other ECM molecules in the effects
described. RNA sequencing databases of aged and young microglia show
increase in multiple ECM molecules in aged microglia, including fibronec-
tin and VCAM (Hickman et al., 2013). Our identification of NG2 expres-
sion in microglia is supported by previous reports that which show that
NG2 expression plays a role in microglia activation in pathological condi-
tions (Sugimoto et al., 2014; Zhu et al., 2016), even though NG2 is gener-
ally regarded as reliable marker for OPCs (Nishiyama, Chang, & Trapp,
1999). Our data and those of others thus confirm that NG2 does not
exclusively identify OPCs.
4.2 | TGFβ directly inhibits OPC differentiation
Since TGFβ was shown to alter OPC differentiation via its effects on
microglia, we further tested whether TGFβ could affect OPCs directly.
Previous reports claimed that TGFβ promotes OPC differentiation
(McKinnon et al., 1993; Palazuelos et al., 2014). In contrast, we find evi-
dence for direct inhibition of OPC differentiation by TGFβ in vitro.
There are a number of possible explanations. The article by McKinnon
et al. (1993) showed an inhibition of proliferation which likely accounted
for an indirect increase in differentiation. In the article by Palazuelos
et al. (2014), the TGFβ effects reported were on cells at a more mature
stage of development (already expressing CNP) than the cells used in
FIGURE 6 TGFβ directly inhibits OPC differentiation in vitro. (a) OPCs were cultured with various concentrations of TGFβ (0–20 ng/mL) for 6 days
in vitro. Differentiation was assessed by CNP staining. The presence of TGFβ in culture media resulted in significant reduction in OPC percentage of
CNP+/OLIG2+ cells (out of total OLIG2+ cells, normalized to control) (one-way ANOVA, n = 3, p value < .05). (b) When cells were cultured with
TGFβ and the addition of TGFβ small molecule inhibitor (SB-431542; 5 μM) differentiation inhibition was eliminated (one-way ANOVA, n = 3,
p value > .05). (c) OPCs cultured with 10 ng/mL TGFβ and the presence of BMP pathway inhibitor (LDN-193189; 5 μM) showed again significant
decrease in differentiation capacities (paired t test, n = 2, p value < .05). (d) Schematic description of pathways blocked by SB-431542 and LDN-
193189. (e) Representative images of OPCs in vitro stained for OLIG2 (red) and CNP (cyan) with or without the addition of TGFβ
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our study. Thus, it is possible that TGFβ has different effects in different
stages of OPC differentiation. This is supported by previous studies in
which higher levels of TGFβ were associated with lower levels of MBP
following focal demyelination (Kotter, Zhao, Van Rooijen, & Frank-
lin, 2005).
Our findings reveal TGFβ as a potential therapeutic target for
enhancement of remyelination in aged patients. These results support
previous studies implicating the harmful effects of TGFβ in ageing,
and specifically in regeneration (Buckwalter et al., 2006). Future
experiments targeting TGFβ by, for example, the administration of TGFβ
pathway inhibitors such as the FDA approved compound Losartan,
could be undertaken to assess their effects on remyelination in aged
animals (Habashi et al., 2011; Holm et al., 2011).
In summary, we report a novel role for microglial ECM in deter-
mining OPC differentiation fate. As microglia constitutes the majority
of the cells in most demyelination lesions (especially during the early
stages of remyelination), these findings could prove important in the
design of remyelination therapies. Moreover, we identify TGFβ as a
key cytokine which can exert inhibitory effects on the differentiation
of OPCs, an effect that increases with ageing.
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